BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Inclusion Criteria: 1. Female patients aged from 18 to 45 years old; 2. Clinical/trichological evidence of telogen effluvium, assessed using the Telogen Index. 3. Participants will be eligible if they have a rate strand of hair ≥ 20% of the total quantified by Thrichoscan measurement in the central-parietal region; 3. Complaint of hair loss for at least 3 months prior to screening; 4. Agreement to obey the procedures and requirements of the protocol and to attend the Research Institution on the day (s) and time (s) determined for the evaluations; 5. Signature of the Informed Consent Form; SAW. Agreement to use an acceptable non-hormonal contraceptive method throughout the period of treatment and up to 60 days after the end of the study; 6. Serum creatinine within the normal range; 7. Relationship between AST / ALT transaminases ≤ 2.5x the upper limit of normal Exclusion Criteria: 1. Pregnancy or pregnancy risk; 2. Lactation; 3. Childbirth occurred in the last 12 months; 4. Patient who has undergone surgical procedures or has suffered trauma in the last 6 months; 5. History of bleeding events in the last 6 months, SAW. Clinical evidence of female androgenic alopecia or alopecia areata; 6. Patients with signs of menopause: menstrual irregularities or cycle failure, signs of climacteric; 7. Laboratory evidence of thyroid diseases (variation in TSH and / or free T4 values outside normal limits); 8. Clinical evidence of ovarian or adrenal endocrine disorders (polycystic ovaries, hirsutism, menstrual irregularities); 9. History or presence of systemic autoimmune disease; 10. Start or end of hormone therapy within 6 months before randomization; 11. Deficiency diseases; 12. Introduction, change or interruption of a hormonal contraceptive method in the last 6 months before randomization; 13. Introduction of a restrictive diet in the last 03 months before randomization; 14. Use of any continuous medication; 15. Diabetes, chronic consuming disease, malabsorptive syndrome or diseases of the gastrointestinal tract; 16. Infectious or chronic fever; 17. Psychiatric/psychological illnesses, such as depression, anxiety or obsessive disorders; 18. Clinical and / or laboratory evidence of anemia or ferropenia; (Hb \<12 g / dL and Ferritin \<40 g / L); 19. Hair treatment to control hair loss (including shampoo, conditioner, lotions); 20. Hair growth agent treatment within 3 months before randomization; 21. Concomitant use of drugs that cause hair loss; 22. Patient with a history of allergic reaction or hypersensitivity to any formulation ingredients; 23. Other conditions considered by the evaluating physician to be reasonable for disqualifying the participation in the study.